Facts and figures

products icon

29.2 million patients use our diabetes products

products icon

Our products are marketed in 170 countries

affiliates icon

We have affiliates in 80 countries


PERFORMANCE

Annual sale 2018


111,831 million Danish kroner 

Q4 2018


29,732 million Danish kroner

Fourth-quarter results for 2018

 

Sales by region
Q4 2018


North America Operations

15,850 million Danish kroner


USA: 15,182 million Danish kroner

Canada: 668 million Danish kroner

 

International Operations

13,882 million Danish kroner


Region Europe: 5,594 million Danish kroner

Region AAMEO: 2,993 million Danish kroner

Region China: 2,712 million Danish kroner

Region Japan & Korea: 1,610 million Danish kroner

Region Latin America: 973 million Danish kroner

 

Sales by business segment
Q4 2018


Diabetes and obesity care total

24,897 million Danish kroner

 

Biopharmaceuticals total

4,835 million Danish kroner

 


R&D AT A GLANCE
 

research icon

We invest 13.2% of sales in R&D
 

employee icon

19% of our global workforce works within R&D

research icon

We have R&D centres in China, Denmark, India, UK and US


We have five main product areas


Diabetes
Obesity
Haemophilia
Growth disorders
Hormone replacement therapy

Product overview
 

Our devices

Diabetes pens and needles
Growth hormone pens
 


OUR PEOPLE

Number of employees

Approximately 42,600 full time employees (FTEs) December 2018.


Business area distribution

19% within research and development

33% in production and production administration

36% in international sales and marketing

12% in administration
 

#

Affiliate distribution (FTEs as of December 2018)

Approximately 40% of employees are located in Denmark (17,091 FTEs) and 60% in the rest of the world:

Africa, Asia, Middle East & Oceania: 7,118 FTEs

China & Taiwan: 4,591 FTEs

Denmark: 17,091 FTEs

Europe (excl. HQ): 4,557 FTEs

Japan (1,137) & Korea: 1,268 FTEs

Latin America: 1,960 FTEs

North America (US 5,784 & Canada 304): 6,088 FTEs

(includes Novo Nordisk and NNE employees)

 


PRODUCTION AT A GLANCE
 

affiliates icon

We supply nearly half the world's insulin

 

Clean energy icon

By 2020 all our production will run on 100% renewable power

research icon

We have production sites in Brazil, China, Denmark, France and the US


HEADQUARTERS

We are located in Denmark

Novo Nordisk A/S
Novo Allé 1
2880 Bagsværd
Denmark
CVR nr. 24 25 67 90

Contact us